Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

780295

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion: Northern Ireland
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what account they took of patient safety and the findings of recent Care Quality Commission reports that Marie Stopes International clinics had been in serious breach of safety guidelines, when deciding to extend the scheme under which free NHS abortions are made available to women from Northern Ireland to include the provision of free travel to those clinics.
tabling member printed	Lord Alton of Liverpool
uin	HL2659
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>Clinics run by Marie Stopes International (MSI) continue to be registered with the Care Quality Commission (CQC) and approved by the Secretary of State to perform abortions. We are aware that CQC inspections raised serious concerns about compliance by MSI clinics with requirements set by the Department and the CQC. MSI are continuing to take a range of actions to address the issues identified in the CQC’s reports. The CQC re-inspected MSI earlier this year and has made clear that they will not hesitate to take further action if necessary, in order to guarantee MSI meets the standard of care they expect and that its patients deserve. The Department continues to closely monitor the situation with particular regard to the statutory approval responsibilities of the Secretary of State.</p> answering member printed Lord O'Shaughnessy question first answered 13/11/2017 13:56:38 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	738 label Biography information for Lord Alton of Liverpool

780348

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in the light of reports that drug-related deaths are increasing in the areas of England where cuts to drug treatment budgets have been among the greatest, whether they intend to establish a national inquiry and action plan to tackle this issue in order to reduce the number of deaths.
tabling member printed	Lord Patel of Bradford
uin	HL2712
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>Public Health England (PHE) led an inquiry last year into the rises in drug-related deaths. The inquiry report, <em>Understanding and preventing drug-related deaths: The report of a national expert working group to investigate drug-related death in England,</em> was published on 9 September 2016 and a copy is attached.</p><p> </p><p>The Government is investing over £16 billion over the current five-year spending review period for local authorities (LAs) to spend on public health. LAs are responsible for making decisions on how to spend their local allocation, but the public health grant conditions make it clear that they must have regard for the need to improve the take up of and outcomes from their drug and alcohol misuse treatment services. Whilst there is considerable variation across the country, with some regions showing large increases in recent years, PHE will continue to support LAs in delivering tailored, accessible and effective services where people stand the best chance of recovery.</p> answering member printed Lord O'Shaughnessy question first answered 13/11/2017 13:58:02 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Understanding and preventing drug related deaths Sept 2016.pdf title Understanding and preventing drug-related deaths
tabling member	3798 label Biography information for Lord Patel of Bradford

780357

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Aphantasia
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they recognise the condition Aphantasia; and, if so, what support is offered to sufferers.
tabling member printed	Lord Storey
uin	HL2721
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>Recognition and classification of disorders is a matter for clinicians and academics in the relevant field. Relatively little is known about aphantasia and the impact it may or may not have on health and wellbeing.</p><p> </p><p>If someone believes they may have the condition and it is impacting on their health and wellbeing they should discuss this with their general practitioner.</p> answering member printed Lord O'Shaughnessy question first answered 13/11/2017 13:57:09 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4238 label Biography information for Lord Storey

780469

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Slaughterhouses: CCTV
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on (a) the number and (b) which slaughterhouses do not have comprehensive CCTV installed on their premises.
tabling member constituency	North West Norfolk
tabling member printed	Sir Henry Bellingham
uin	110364
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>In May 2016 the Food Standards Agency carried out a CCTV survey in all 278 operating slaughterhouses in England and Wales.</p><p> </p><p>The results from this survey showed:</p><p> </p><p>- 102 out of 207 red meat slaughterhouses (49.3%) and 50 out of 71 white meat slaughterhouses (70.4%) had some form of CCTV in use for animal welfare purposes.</p><p> </p><p>In respect of which slaughterhouses do not have comprehensive CCTV installed on its premises, this information is commercially sensitive and cannot be released.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/11/2017 11:53:02 answering member 4067 label Biography information for Steve Brine
tabling member	1441 label Biography information for Lord Bellingham

780493

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to improve the sharing of medical records between medical institutions and trusts for mental health service users.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	110444
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Government recognises that appropriate and timely sharing of data is essential to improving care, treatment and support for service users. We are committed to ensuring the health and social care system in England realises the benefits of sharing data in a safe, secure and legal way.</p><p> </p><p>Government policy has outlined the importance of sharing data between organisations at a local level. The Department has worked with the Centre of Excellence for Information Sharing to understand the factors which impact on information sharing in mental health crisis care.</p><p> </p><p>Challenges around transferring patient notes and records between different organisations and care settings are recognised and will be addressed, in part, by the move from paper records to electronic systems for recording and sharing patient information.</p><p> </p><p>‘Information: To Share or not to share? The Information Governance Review’ (2013) created a duty on National Health Service trusts to share information. NHS trusts have to demonstrate in their annual information governance return how they are fulfilling this duty.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 07/11/2017 17:11:35 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4658 label Biography information for Alex Sobel

780497

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Homes: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with Cabinet colleagues on the potential merits of introducing a cap on care costs for older people.
tabling member constituency	Stafford
tabling member printed	Jeremy Lefroy
uin	110249
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Government will work to address the challenges of social care for our ageing population, bringing forward proposals for consultation to build widespread support. We are committed to listening to people’s views on how to reform the social care system, to ensure it is sustainable for current and future generations and that the quality of care improves.</p><p> </p><p>Ageing and care issues span a number of areas for which different Departments have policy responsibility, which is why the Cabinet Office will continue to coordinate this work through its next phase, working closely with HM Treasury and the Departments of Health, Communities and Local Government, Work and Pensions, and Business, Energy and Industrial Strategy.</p><p> </p><p>We will consult on options which will include a capital floor and an absolute limit on the amount people who can be asked to pay, and are keen to hear different views on the cap, both its level and design.</p><p> </p><p>We will provide further details on the next steps on social care in due course.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 110250 question first answered 07/11/2017 17:09:59 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4109 label Biography information for Jeremy Lefroy

780498

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Social Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, on what timeline he plans to consult on and publish a Green Paper on adult social care.
tabling member constituency	Stafford
tabling member printed	Jeremy Lefroy
uin	110250
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Government will work to address the challenges of social care for our ageing population, bringing forward proposals for consultation to build widespread support. We are committed to listening to people’s views on how to reform the social care system, to ensure it is sustainable for current and future generations and that the quality of care improves.</p><p> </p><p>Ageing and care issues span a number of areas for which different Departments have policy responsibility, which is why the Cabinet Office will continue to coordinate this work through its next phase, working closely with HM Treasury and the Departments of Health, Communities and Local Government, Work and Pensions, and Business, Energy and Industrial Strategy.</p><p> </p><p>We will consult on options which will include a capital floor and an absolute limit on the amount people who can be asked to pay, and are keen to hear different views on the cap, both its level and design.</p><p> </p><p>We will provide further details on the next steps on social care in due course.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 110249 question first answered 07/11/2017 17:09:59 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4109 label Biography information for Jeremy Lefroy

780510

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's publications Biological Medicines Commissioning Framework published on 12 September 2017 and What is a Biosimilar Medicine published on 24 September 2015, what steps he has taken to ensure that patients in England will have the right to an informed discussion and consultation with their clinician before a decision is made to switch them from their existing biologic treatment to a biosimilar treatment.
tabling member constituency	West Ham
tabling member printed	Lyn Brown
uin	110267
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>NHS England is clear that treatment decisions should always be made first on the basis of clinical judgement and through shared decision making with individual patients. Where a decision is taken to switch a patient from their existing biologic treatment to a biosimilar treatment, strong safeguards are required to ensure that patients who have responded well to existing medicine are closely monitored to ensure efficacy and safety.</p><p> </p><p>NHS England is working closely with patient groups to develop patient material which will help patients to have informed discussions with a clinician. NHS England met with a number of patient groups in August 2017 to discuss biosimilar medicines and is committed to continuing a collaborative working relationship. NHS England recognises patient groups have an important role to play as advocates for biosimilar medicines and in the process, provide peer to peer support for patients.</p><p> </p><p>NHS England is also working with NHS Choices to ensure the availability of biosimilars related information to support patients to make informed decisions about switching, and help patients understand what biosimilar medicines are. NHS Choices are updating their current biological medicine content to align with NHS England's commissioning framework.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/11/2017 17:16:36 answering member 4067 label Biography information for Steve Brine
tabling member	1583 label Biography information for Ms Lyn Brown

780518

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans NHS England has to (a) engage with patient groups to explain biosimilar medicines and (b) discuss how such medicines can be integrated into patient care in a safe and sustainable way.
tabling member constituency	West Ham
tabling member printed	Lyn Brown
uin	110182
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>A national Biosimilar Medicines Programme Board, chaired by NHS England’s Chief Pharmaceutical officer, Dr Keith Ridge, was established in 2015. The Board provides strategic advice and direction to NHS England in relation to a national programme of work focused on increasing access and uptake of biosimilar medicines, in a safe and sustainable way. Patient groups are represented on this board and other delivery partners include:</p><p> </p><p>- The Association of the British Pharmaceutical Industry;</p><p>- The British Generic Manufacturers Association;</p><p>- The National Institute for Health and Care Excellence;</p><p>- Medicines and Healthcare products Regulatory Agency;</p><p>- Clinicians;</p><p>- Commissioners; and</p><p>- NHS England and Departmental Policy Makers.</p><p> </p><p>The board has overseen three specific strands of work:</p><p> </p><p>- Development of a Commissioning Framework;</p><p>- Development of a set of indicators for biosimilar medicines; and</p><p>- A communication and education work stream.</p><p> </p><p>A sub group comprising membership from the national Biosimilar Medicines Programme Board, including patient group representation, was established to look at communication and education material for biosimilars. This group will continue to play a pivotal role in terms of ensuring consistency in key messages to the public.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/11/2017 17:19:11 answering member 4067 label Biography information for Steve Brine
tabling member	1583 label Biography information for Ms Lyn Brown

780519

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many Yellow Cards submitted to the Medicines and Healthcare Products Regulatory Agency for the HPV vaccination were classified as serious; and how many of those cases were reviewed to establish whether the patient had returned to full health in each of the last 12 months.
tabling member constituency	Mansfield
tabling member printed	Ben Bradley
uin	110360
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) encourages anyone to report a suspected adverse reaction (ADR) to a vaccine or medicine through the Yellow Card Scheme:</p><p> </p><p><a href="http://www.mhra.gov.uk/yellowcard" target="_blank">www.mhra.gov.uk/yellowcard</a></p><p>A Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine or medicine may have been the cause. Such reports are kept under continual review to identify potential new risks.</p><p> </p><p>Between 31 October 2014 – 30 October 2017 a total of 649 serious suspected adverse reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme (data run date: 1 November 2017). In this three year period, at least 1 million doses of HPV vaccine were administered in the United Kingdom.</p><p> </p><p>A breakdown of UK serious suspected spontaneous ADR reports received via the Yellow Card Scheme beween 31 October 2014 – 30 October 2016 by brand and year received is shown in the following table.</p><p> </p><table><tbody><tr><td><p>HPV Vaccine</p></td><td><p>Number of serious reports</p></td></tr><tr><td><p>HPV brand unspecified</p></td><td><p>181</p></td></tr><tr><td><p>Cervarix</p></td><td><p>64</p></td></tr><tr><td><p>Gardasil</p></td><td><p>390</p></td></tr><tr><td><p>Gardasil 9</p></td><td><p>18</p></td></tr><tr><td><p>Total</p></td><td><p>649</p></td></tr></tbody></table><p> </p><p>Source: MHRA sentinel database for adverse reactions</p><p> </p><p>Notes:</p><p> </p><p>The total number of reports received by vaccine brand is not equal to the totals in the table above as some reports included more than one HPV vaccine brand.</p><p> </p><p>The MHRA has received a total of 3,159 serious suspected adverse reaction reports associated with HPV vaccine (data run date 1 November 2017).</p><p> </p><p>All serious reports received via the Yellow Card Scheme are reviewed based on the details received from the reporter. Follow up letters may be sent for missing information such as vaccine brand name, batch number, medical history, results of investigations, diagnoses and details of outcome.</p><p> </p><p>The Commission on Human Medicines has thoroughly reviewed the safety of HPV vaccines and concluded that the evidence does not support a link between HPV vaccination and the development of chronic illnesses.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110248 question first answered 07/11/2017 11:31:40 answering member 4067 label Biography information for Steve Brine
tabling member	4663 label Biography information for Ben Bradley